Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

J&J sees sales growth in near-term; raises 2017 profit forecast

07/18/2017 | 02:44pm EST
A Johnson & Johnson building is shown in Irvine, California

(Reuters) - Johnson & Johnson (>> Johnson & Johnson) said it expects sales growth to pick up in the second half of the year on strong demand for newer, pricey treatments such as cancer drugs Darzalex and Imbruvica.

(Reuters) - Johnson & Johnson (>> Johnson & Johnson) said it expects sales growth to pick up in the second half of the year on strong demand for newer, pricey treatments such as cancer drugs Darzalex and Imbruvica.

J&J, which reported better-than-expected quarterly earnings and raised its full-year profit forecast on Tuesday, is banking on newer pharmaceuticals to counter slowing demand for some of its older, best-selling products, including Remicade and diabetes drug Invokana.

J&J's shares were up 1.9 percent at $134.64 in afternoon trading on the New York Stock Exchange.

Chief Executive Alex Gorsky said that when drugs add months or years to patient lives and make significant differences on health outcomes, as with multiple myeloma treatment Darzalex and leukemia drug Imbruvica, the company has experienced less pricing pressure.

The price tag for the first year of treatment of Darzalex is around $140,000. A year's supply of Imbruvica capsules costs around $120,000.

Pharmaceutical companies have come under pressure to cut prices from insurers and the federal government. J&J is one of several companies that have said they will keep annual price increases mostly below 10 percent.

President Donald Trump has said that he will work to bring down drug prices.

J&J is the first among major pharmaceutical companies to release quarterly results. The report comes a day after a Republican effort to pass healthcare legislation in the Senate collapsed. Gorsky was in Washington, D.C., on Tuesday meeting with U.S. and global leaders to discuss healthcare-related issues.

Excluding special items, J&J, which also makes medical products and consumer products including Band-Aids, earned $1.83 per share in the second quarter, beating analysts' estimates by 3 cents.

While sales in J&J's consumer and medical device divisions rose, sales for pharmaceutical products - its largest business - fell marginally to $8.6 billion.

This is the third quarter in a row that J&J's pharmaceutical sales have fallen short of estimates, RBC Capital analysts said in a research note.

"There appears to be a light at the end of the tunnel," BMO Capital Markets analyst Joanne Wuensch said, citing Darzalex's expanded label and the U.S. Food and Drug Administration's recent nod for J&J's potentially blockbuster psoriasis treatment, Tremfya.

The diversified healthcare company, which completed its $30 billion acquisition of Swiss biotech Actelion (>> Actelion) last month, raised its 2017 profit forecast to a range of $7.12 to $7.22 per share, from a range of $7.00 to $7.15.

(Reporting by Michael Erman in New York and Divya Grover in Bengaluru; Additional reporting by Natalie Grover in Bengaluru; Editing by Bernard Orr and Leslie Adler)

By Michael Erman and Divya Grover

Stocks treated in this article : Johnson & Johnson, Actelion

© Reuters 2017
Stocks mentioned in the article
ChangeLast1st jan.
BEST INC. -2.22% 0.8823 Delayed Quote.3.62%
JOHNSON & JOHNSON -0.44% 167.1 Delayed Quote.-2.32%
SWISS RE LTD 0.91% 97.88 Delayed Quote.7.47%
All news about JOHNSON & JOHNSON
01/17Johnson & Johnson Statement on New Mexico Opioid Settlement Agreement
AQ
01/17MARKETSCREENER’S WORLD PRESS REVIEW : January 17, 2022
01/17Midatech Pharma, Janssen Extend R&D Partnership On Experimental Medicine
MT
01/14European Medicines Agency Asks AstraZeneca, Johnson & Johnson To Add Spinal Inflammatio..
MT
01/13Divco West Real Estate Services, LLC acquired 143,000 square feet, 5000 Shoreline Court..
CI
01/12Johnson & Johnson's COVID-19 Vaccine Fact Sheet Updated to Include Risk of Rare Bleedin..
MT
01/12South African Institute To Study Effects Of Pfizer, BioNTech, Johnson & Johnson Booster..
MT
01/11US FDA Adds Risk of Rare Bleeding Disorder to Johnson & Johnson COVID-19 Jab's Fact She..
MT
01/11Mix and Match Covid-19 Vaccine Study to Take Place in Mozambique
AQ
01/10Johnson & Johnson Mulls Inorganic Opportunities
CI
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 306 M - -
Net income 2021 22 542 M - -
Net Debt 2021 596 M - -
P/E ratio 2021 19,8x
Yield 2021 2,48%
Capitalization 440 B 440 B -
EV / Sales 2021 4,67x
EV / Sales 2022 4,35x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 167,10 $
Average target price 183,50 $
Spread / Average Target 9,81%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Alex Gorsky Executive Chairman
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-2.32%441 855
ROCHE HOLDING AG-3.10%325 363
PFIZER, INC.-6.94%308 427
ABBVIE INC.0.35%240 202
NOVO NORDISK A/S-15.01%223 075
ELI LILLY AND COMPANY-11.62%221 317